NeoGenomics shares rose 4.1% following Q1 2026 results, as revenue growth, margin improvement, and NGS expansion topped expectations. Revenue surpassed guidance, with clinical and NGS businesses driving performance and improved profitability.

• Total Q1 revenue reached $186.7 million, up 11% year-over-year and ahead of previously issued guidance.
• Adjusted EBITDA was $9 million, increasing 27% over the prior-year period, with a 60 basis point margin improvement.
• Clinical revenue rose 14% year-over-year to $171 million, fueled by 8% growth in average unit price (AUP) and 6% volume growth.
• NGS revenue expanded 26% year-over-year, now accounting for one-third of clinical revenue, and growing well ahead of the broader NGS market rate.
• Recent acquisitions and product launches, including the Pathline integration and PanTracer liquid biopsy, are positioned to sustain above-market growth and share gains in the community oncology segment.